Get started
Author

Mária Rečková

Observed names: M Reckova, M Recková, M Rečková, M. RECKOVA, M. Reckova, M. Recková, M. Rečkova, Maria RECKOVA, Maria Reckova
Observed institutions: Medical University of South Carolina, Slovak Academy of Sciences, University of Münster, Národný Onkologický Ústav, National Cancer Institute, Biomedical Research Center of the Slovak Academy of Sciences, National Cancer Institute, National Cancer Institute, Comenius University Bratislava, University of Lausanne
ORCID: 0000-0002-5065-7778
Observed ORCID: 0000-0002-5065-7778
OpenAlex ID: A5046500018
Prevention of irinotecan induced diarrhea by probiotics: A randomized double blind, placebo controlled pilot study
2015 · Michal Mego, Jozef Chovanec, et al. · Complementary Therapies in Medicine · 246
Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial
2014 · Karim Fizazi, Lance Pagliaro, et al. · The Lancet Oncology · 211
Functional and morphological evidence for a ventricular conduction system in zebrafish andXenopushearts
2003 · David Sedmera, Maria Reckova, et al. · American Journal of Physiology-Heart and Circulatory Physiology · 201
Hemodynamics Is a Key Epigenetic Factor in Development of the Cardiac Conduction System
2003 · Maria Reckova, Carlin Rosengarten, et al. · Circulation Research · 187
Spatiotemporal pattern of commitment to slowed proliferation in the embryonic mouse heart indicates progressive differentiation of the cardiac conduction system
2003 · David Sedmera, Maria Reckova, et al. · The Anatomical Record Part A Discoveries in Molecular Cellular and Evolutionary Biology · 133
PDF
Hemodynamic-dependent patterning of endothelin converting enzyme 1 expression and differentiation of impulse-conducting Purkinje fibers in the embryonic heart
2004 · Christopher E. Hall, Romulo Hurtado, et al. · Development · 111
Phase II study of avelumab in multiple relapsed/refractory germ cell cancer
2019 · M. Mego, D. Svetlovska, et al. · Investigational New Drugs · 86
Developmental transitions in electrical activation patterns in chick embryonic heart
2004 · David Sedmera, Maria Reckova, et al. · The Anatomical Record Part A Discoveries in Molecular Cellular and Evolutionary Biology · 62
PDF
Phase II study of everolimus in refractory testicular germ cell tumors
2015 · Michal Mego, Daniela Svetlovska, et al. · Urologic Oncology Seminars and Original Investigations · 53
Bevacizumab in a growing teratoma syndrome. Case report
2007 · M. Mego, M. Recková, et al. · Annals of Oncology · 53
Increased cardiotoxicity of sorafenib in sunitinib-pretreated patients with metastatic renal cell carcinoma
2007 · M. Mego, M. Reckova, et al. · Annals of Oncology · 52
Paclitaxel plus ifosfamide and cisplatin in second-line treatment of germ cell tumors: a phase II study.
2005 · J Mardiak, T Sálek, et al. · PubMed · 47
Patient With Malignant Paraganglioma Responding to the Multikinase Inhibitor Sunitinib Malate
2008 · Noah M. Hahn, Maria Reckova, et al. · Journal of Clinical Oncology · 45
Safety and efficacy of inactivated varicella zoster virus vaccine in immunocompromised patients with malignancies: a two-arm, randomised, double-blind, phase 3 trial
2019 · Kathleen M Mullane, Vicki A Morrison, et al. · The Lancet Infectious Diseases · 39
The Oldest, Toughest Cells in the Heart
2003 · Robert P. Thompson, Maria Reckova, et al. · Novartis Foundation symposium · 34
Optical Mapping of Electrical Activation in the Developing Heart
2005 · David Sedmera, Maria Reckova, et al. · Microscopy and Microanalysis · 33
Personalized Chemotherapy on the Basis of Tumor Marker Decline in Poor-Prognosis Germ-Cell Tumors: Updated Analysis of the GETUG-13 Phase III Trial
2024 · Karim Fizazi, Gwénaël Le Teuff, et al. · Journal of Clinical Oncology · 26
Randomized double-blind, placebo-controlled multicenter phase III study of prevention of irinotecan-induced diarrhea by a probiotic mixture containing Bifidobacterium BB-12®Lactobacillus rhamnosus LGG® in colorectal cancer patients
2023 · Michal Mego, Radoslav Danis, et al. · Frontiers in Oncology · 26
PDF
Phase II study of Disulfiram and Cisplatin in Refractory Germ Cell Tumors. The GCT-SK-006 phase II trial
2022 · M Mego, D Svetlovska, et al. · Investigational New Drugs · 26
Patterns of relapse in poor-prognosis germ-cell tumours in the GETUG 13 trial: Implications for assessment of brain metastases
2017 · Y. Loriot, L. Pagliaro, et al. · European Journal of Cancer · 23
Gemcitabine, carboplatin and veliparib in multiple relapsed/refractory germ cell tumours: The GCT-SK-004 phase II trial
2021 · M. Mego, D. Svetlovska, et al. · Investigational New Drugs · 22
Cost-effectiveness of colorectal cancer screening in Slovakia
2021 · Robert Babela, Andrej Orsagh, et al. · European Journal of Cancer Prevention · 17
Mature results of the GETUG 13 phase III trial in poor-prognosis germ-cell tumors (GCT).
2016 · Karim Fizazi, Aude Flechon, et al. · Journal of Clinical Oncology · 17
Sunitinib in Patients with Cisplatin-Refractory Germ Cell Tumors
2012 · Maria Reckova, Michal Mego, et al. · Onkologie · 15
Small-cell carcinoma of the ovary with breast metastases: a case report.
2010 · M Reckova, M Mego, et al. · PubMed · 15
Works count: 60
Citation count: 1,876
H-index: 21
I10-index: 28
Year
Topic
Type